Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kennedy/Frist: $100 Mil. For FDA Bioterrorism Product Review, Food Safety

Executive Summary

Sens. Bill Frist (R-Tenn.) and Edward Kennedy (D-Mass.) are requesting $100 mil. to improve FDA review of products and food safety related to bioterrorism.

You may also be interested in...



Merck Considers Smallpox Vaccine; Four Companies In Discussions With HHS

Merck is among the companies involved in discussions with HHS regarding manufacture of smallpox vaccine.

Pharma Readies For Bioterrorism: BIO Survey Says Security Systems Adequate

A Biotechnology Industry Organization survey of approximately 1,000 member companies indicates that the biotech industry's security systems are adequate in the case of a bioterrorist attack.

Pharma Readies For Bioterrorism: BIO Survey Says Security Systems Adequate

A Biotechnology Industry Organization survey of approximately 1,000 member companies indicates that the biotech industry's security systems are adequate in the case of a bioterrorist attack.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel